Slide 1: NeurAxis, Inc
NeurAxis, Inc Reimagining an Evidence-Based, Drug Free Alternative For Children NeurAxis is committed to providing solutions that create value and provide better patient outcomes. We believe in improving lives and minimizing suffering, Through innovation and research, we are reimagining the future o
Slide 2: Forward Looking Statements
Forward Looking Statements Information included herein has been prepared by NeurAxis Inc, (*NeurAxis") or obtained from sources believed to be reliable, but the accuracy or completeness of such information isnot guaranteed by and should not be construed asa representation by NeurAxis or any ather pe
Slide 3: NeurAxis PENFS: First FDA Indicated Treatment for Pediatric FAP/IBS
NeurAxis PENFS!: First FDA Indicated Treatment for Pediatric FAP/IBS2 Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth Large Global Market with Significant Unmet Need + $3081 TAM? for target pipeline indications * $98 TAM? for target pediatric indications (near-to- mid te
Slide 4: $30B+ Total Addressable U.S. Market for Pipeline Indications
$30B+ Total Addressable U.S. Pediatric Indications $18 nv ‘ea $9B Pediatric TAM* S18 FaPBS fina nctiona Dyspepsia (Nausea) Market for Pipeline Indications Adult Indications $98 Oyetc vomiting Why Pediatrics? * Significant unmet need * Lack of FDA approved treatment options * Single call point for fu
Slide 5: DGBIs: A Problem with an Unmet Need
DGBIs: A Problem with an Unmet Need + No FDA-approved therapies for children with abdominal pain-related disorders of the gut-brain interactions (DGBIs) + Disorders negatively impact quality of life and ability to function (attend school, sports, and social activities) 7 y + Insufficient data to sup
Slide 6: Abnormal processing of signals to and from the gut
Abnormal processing of signals to and from the gut J Gut Brain Axis Disorders of the Gut-Brain Interaction (DGBIs) Irritable Cyclic Bowel Vomiting Syndrome Syndrome Functional Dyspepsia Gastroenterology Eunctional Dyspepsia ~ pain or discomfort located in the upper abdomen Irritable Bowel Syndrome (
Slide 7: Data Does Not Support Standard Pharmacotherapy in Children with IBS
Data Does Not Support Standard Pharmacotherapy in Children with IBS No data to support use of Antidepressants in Children with Functional Abdominal Pain: + Amitriptyline (TCA) did not beat placebo in RCT! + Citalopram (SSRI) did not beat placebo in RCT? Significant Risk of TCA Side Effects in Childr
Slide 8: Percutaneous Electrical Nerve Field Stimulation (PENFS)
Percutaneous Electrical Nerve Field Stimulation (PENFS) (00) 1. Access —— 2. Stimulate §=-———~+ Direct access to central Stimulation reduces firing nervous system (CNS) of amygdala through peripheral cranial nerves “Facil (Vt) “Glossopharyngeal Sous 09 i] 3. Change Induces changes in brain pathways/
Slide 9: Established Technology with Demonstrated Safety and Efficacy
Established Technology with Demonstrated Safety and Efficacy What is IB-Stim™ * PENES system intended for patients 11-18 years of age with functional abdominal pain (FAP) associated with IBS * Aids in pain reduction via neuromodulation to branches of Cranial Nerves (V,VIL,X and X) * Non-drug and non
Slide 10: IB-Stim Advantages Over Traditional Care
IB-Stim™ Advantages Over Traditional Care MST Tacitional care FDA Indicated fy) No FDA Approved i Treatments Rx often eseal Paley 4 Peratanaovs Electial Nowe Field Stimulation or ritsble Bowal nha a Containing FDA pie ee Black Box Labels Suicidal Ideation, Pot Mune 82 Minimal Side Effects Depression
Slide 11: Patient Journey
Patient Journey Qj 2. Consultation General Pe rician * Pain is generalized, non-specific, showing no “red flags" * Counsels on lifestyle changes Families often skip PCP since referral is not required. y, * If no benefit, trial of medication mG * If no benefit referral to Pediatric Gastroenterologist
Slide 12: IB-Stim Research — By the Numbers
IB-Stim™ Research — By the Numbers Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth i 1 Current Publications Utilizing NeurAxis' PENFS Technology 1 @) Types of Studies 1 3 Children’s Hospital Study Sites Double Blind Long-Term Eze Registry Rest .ed Placebo Controlled Data
Slide 13: IB-Stim Publications in Children with DGBIs
1B-Stim Publications in Children with DGBIs Percutaneous Electrical Nerve Field Stimulation Compared to| ‘Standard Medical Therapy in Adolescents with Functional ‘Abdominal Pain Disorders Effect of percutaneous electrical nerve field stimulation on ‘mechanosensitivity, sleep, and psychological comor
Slide 14: Improvement of Global Symptoms in Patients with Irritable Bowel Syndrome
THE LANCET Nov Improvement of Global Symptoms in Patients Gastroenterology & Hepatology2017 with Irritable Bowel Syndrome Global Symptom Improvement 100 0. 82 2 0 6 o % 50 “8 PENIS 40 * # OSham eo bas 22 22 20 10 oT T T i] 22 23 24 “Percent of patients reporting improvement of global symptoms using
Slide 15: FDA Benchmark for Clinically Meaningful Endpoint
FDA Benchmark for Clinically Meaningful Endpoint 230% Improvement in Pain 10" 2 IB-Stim Treatment for abdominal pain-related functional = Sham a 6 9 2 gastrointestinal disorders in adolescents: cor g 50" Number Needed to Treat (NNT): La The number of patients that need to be treated for one patient
Slide 16: Functional Disability Scores at Long-Term Follow-Up
Functional Disability Scores at Long-Term Follow-Up Improvement in Functional Disability in Patients with Irritable Bowel Syndrome e Moderate disability Minimal disability a os Improving functional disability 2 * (attending school and activities) is a 10 marker of overall health and clinically 8 mea
Slide 17: A multicenter registry study on PENFS for pediatric DGBIs
A multicenter registry study on percutaneous electrical nerve field stimulation for pediatric disorders of gut-brain interaction Ashish Chogle' | Khalil El-Chammas* | Neha Santucci | Monica Grimm? | Lev Doriman® | Kahleb Graham* | Danie! R.Kelly’ | Jason E. Dranove' | Rachel Rosen* | Samuel Nurko* |
Slide 18: PENFS compared to standard medical therapy in adolescents
‘ee ie Neha R. Santuce! Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders ™, Rash Sahay, Khali. l-Charnnas Kahleb Graham, Mikaela Wheatey", Madeleine Vandenbin Jennifer Hardy’ and Lin Fei IB-Stim was equivalen
Slide 19: IB-Stim vs. Drugs Competitive Landscape
IB-Stim™ vs. Drugs Competitive Landscape Antidepressants Adult Use (Peripherally Acting at the Gut Level) IB-Stim™ Amitriptyline Citalopram Amitiza Linzess Trulance Viberzi FDA Approved for 18S in Wi Children and Adolescents Improves Functional Disability Targets Brain-Gut Axis Better Than Placebo f
Slide 20: FDA Pipeline - Indications and Timelines
FDA Pipeline - Indications and Timelines Indication 2023E 2024E 2025E jal Abdominal Pain & Irritable indrome - Pediatric FDA Submission FDA Indication 2026E 2027E Launch / Commercialization Clinical Study* Children's isconsin RCT** Multi-center Prospective Children's Hospital of (Orange County RCT**
Slide 21: Expanding Portfolio of Next Generation Devices for DGBIs
Expanding Portfolio of Next Generation Devices for Disorders of Gut-Brain Interaction RECTAL EXPULSION DEVICE [RED] . Developed at the University of Michigan enabling comprehensive constipation care for every adult gastroenterology practice RED is a self-inflating balloon expulsion test that allows
Slide 22: IB-Stim Reimbursement
IB-Stim Reimbursement Market Access Plan Established * Versus Placebo + NASPGHAN Written Support + CareFirst BCBS + BCBS Kanass City + CAT Ill (Effective July 2022) + Long-term Data x 2 + AAP Written Support + BSBS Nebraska + Highmark BCBS + CAT | Application (June 2024) + Comparison vs. Soc Rx + Qu
Slide 23: IB-Stim Go-to-Market Strategy
IB-Stim Go-to-Market Strategy Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth 2024 Policy Coverage Commercialization Strate; Reimbursement Strategy 8 plans tome cet code + CATII code (07207) =a CareFirst BCBS 35M. atine * $4,195 BCBS of MA 3M = 5 Developed ROL Calculator
Slide 24: NeurAxis IP Portfolio issued and pending patents
NeurAxis IP Portfolio 11 issued and 9 pending patents = Device * Method U.S. IP runs through 2039 as of now International IP in process Freedom to operate completed
Slide 25: Collaborative Contract Manufacturing Partnership
Collaborative Contract Manufacturing Patni In-House Capabilities Manufacturing Capacity Quality Management System + Office and factory in Indiana + Controlled, repeatable, monitored + ISO 13485:2016 Certified + 69,000 square foot facility production process + FDA registered * Offices, factory, envir
Slide 26: Medical Advisory Board
Medical Advisory Board Dr. Samuel Nurko Dr. Carlo Di Lorenzo Dr. Rachel Rosen. Dr. Kahlil El-Chammas Dr. Miranda van Tilburg Dr. Leonel Rodriguez Boston Boston 2] Childrens NATIONWIDE Children's i UN o Hospital CHILDRENS Hospital — breteeatrenis Unitevery chilis well” haya mmm Unt every child is wet
Slide 27: Board of Directors
Board of Directors Beth Keyser Mitch Watkins Kirstin Ferge Brian Carrico Dr. Chris Brown Board Member Board Member Board Member Chief Executive Officer, Director Of Innovation, Board Member Founder, Board Member Collective Experience mac Anthem Kea ® TERUMO Capri > St. JUDE MEDICAL Q_feaithipin Sexc
Slide 28: Management Team
Management Team i Brian Carrico Dr. Adrian Miranda Chief Executive Officer, Chief Medical Officer Board Member sr JUDE MEDICAL BA MEDICAL [BARID four OF WISCONSIN Children’s Hospital of Wists © Timothy Henrichs Chief Financial Officer Dan Clarence Dr. Tom Carrico Dr. Chris Brown Chief Operating Offi
Slide 29: Key Investment Highlights
Key Investment Highlights Strong Data = Strong Policy Coverage & Reimbursement = Strong Revenue Growth Large Global Market with Significant Unmet Need * $30B+ TAM? for target pipeline indications + 598+ TAN for target pediatric indications (near-to-mid term) + 5218+ TAM? for target adult indications